Skip to main content

Carmen Espejo Ruiz

I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies.

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Carmen Espejo Ruiz

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies.

I obtained my degree in Biology from the University of Barcelona in 1998. I did my doctoral thesis at the Clinical Neuroimmunology Unit of the Hospital Universitari Vall d'Hebron, in which I studied the role of metallothioneins in the pathogenesis of multiple sclerosis, obtaining my PhD in Biology from the University of Barcelona in 2005. In 2008, I got a Miguel Servet contract that allowed me to establish myself as principal investigator of the Clinical Neuroimmunology group – Multiple Sclerosis Centre of Catalonia. Currently, I am a senior researcher at the Vall d'Hebron Research Institute and develop my scientific activity in the Clinical Neuroimmunology group - Center d'Esclerosi Múltiple de Catalunya.
My main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim of developing new therapeutic strategies. I am currently focused on the role of immunosenescence in the pathogenesis of multiple sclerosis and the therapeutic potential of different senolytic drugs. I am also studying how the modification of the gut microbiota, through the administration of probiotics, could constitute a therapeutic tool in multiple sclerosis. Finally, I am carrying out a project that aims to induce immune tolerance, through the use of nanomedicine, with the aim of slowing down the autoimmune response in multiple sclerosis. I have more than 25 years of experience in animal models of multiple sclerosis and in the study of the immune response.
At the Vall d'Hebron Research Institute, I am a member (since 2003) and the president (since 2006) of the Animal Experimentation Ethics Committee. I am also part of the Biosafety Committee (since 2015) and the Research Integrity Committee (since 2020).
I have participated, as main or collaborating author, in 70 publications indexed in peer review journals. I have supervised eight doctoral theses and eight master's final projects. In addition, I participated as a teacher in various training activities, including the Master of Advanced Immunology at the Autonomous University of Barcelona and the University of Barcelona.

Projects

United Europeans for the development of Pharmacogenomics in Multiple Sclerosis (UEPHA-MS) Grant Agreement Nº 212877

IP: Manuel Comabella Lopez
Collaborators: Jordi Rio Izquierdo, Carmen Espejo Ruiz
Funding agency: EUROPEAN COMMISSION
Funding: 185749.7
Reference: UEPHA-MS_FP7PEOPLE_ITN2008
Duration: 15/09/2008 - 14/09/2012

¿Participan las proteínas de choque térmico (heat shock protein) en el desarrollo de la Esclerosis Múltiple?

IP: Carmen Espejo Ruiz
Collaborators: -
Funding agency: Fundación Caja Navarra
Funding: 760.5
Reference: CAN2008-15272
Duration: 01/01/2009 - 31/12/2009

¿Podemos retrasar o evitar la neurodegeneración en la Esclerosis Múltiple?

IP: Carmen Espejo Ruiz
Collaborators: -
Funding agency: Fundación Caja Navarra
Funding: 15753.98
Reference: CAN2009-16365
Duration: 01/01/2010 - 31/12/2010

Función de las proteínas de choque técnico (HSP, heat shock protein)-70 en la patogenia de la esclerosis múltiple

IP: Función de las proteínas de choque técnico (HSP, heat shock protein)-70 en la patogenia de la esclerosis múltiple
Collaborators: Carmen Espejo Ruiz, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109804.5
Reference: MS07/00146
Duration: 01/01/2008 - 31/12/2013

Related news

A study conducted at the Catalan Multiple Sclerosis Centre (Cemcat) shows that the lack of a reduction in neurofilament light chain during the first year of treatment is associated with a higher risk of subsequent disease activity.

The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.

An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.

Related professionals

Maria Baladas Orti

Maria Baladas Orti

Research technician
Stroke research
Read more
Laura Rubio Guerrero

Laura Rubio Guerrero

Gestió i Administració
Purchase and Biddings Unit
Finance Directorate
Read more
Javier Francisco Ramón Pasías

Javier Francisco Ramón Pasías

Postdoctoral researcher
Neuromuscular and Mitochondrial Pathology
Read more
Sandra Rojas Nieto

Sandra Rojas Nieto

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.